Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?

0:00-36:28

In this episode of Diagnosing Dx, David Filby is joined by Alexander Bagaev, Chief Product Officer at BostonGene. Alexander has spent more than a decade helping build BostonGene from an early-stage team into a global precision medicine company. In this conversation, we explore why oncology is moving beyond single biomarkers and how BostonGene has expanded from diagnostics into AI-powered treatment selection and clinical trial support. We also discuss the challenge of bringing more comprehensive diagnostics into routine use, the role of multimodal data in better decision-making, and how BostonGene is working with pharma to design smarter trials from the outset. This is a practical conversation about precision oncology, multimodal diagnostics, AI in drug development, and turning complex biology into clinically useful decisions.

Publisher

Diagnosing Dx

Published

July 15, 2026

Duration

36 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Elevra Consulting

DD

Diagnosing Dx

@diagnosingdx

#airescuecancer #clinicaltrials #failed #lifesciences

The Nile